Post-Market Data Published in European Journal of Vascular and Endovascular Surgery (EJVES)

The manuscript for the multicenter experience of 164 HeRO Graft implants has recently been accepted for publication to the European Journal of Vascular and Endovascular Surgery (EJVES).¹

This data is a retrospective look at HeRO Graft patients from four centers with clinical follow up to two years.

KEY POINTS:
This is the largest review to date with 24 month follow up on the performance of the HeRO Graft in terms of the infection rate, patency and interventions.

<table>
<thead>
<tr>
<th></th>
<th>1 Year</th>
<th>2 Years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary patency</td>
<td>48.8%</td>
<td>42.9%</td>
</tr>
<tr>
<td>Secondary patency</td>
<td>90.8%</td>
<td>86.7%</td>
</tr>
</tbody>
</table>

• Infection rate*: 0.14/1,000 days
• Intervention rate: 1.5 per year

*Device related

• HeRO Graft performed comparably to standard AV grafts and superior to Tunneled Dialysis Catheters (TDCs) in terms of the infection rate, patency and interventions.

• Conclusion: “As an alternative to catheter dependence as a means for hemodialysis access, the [HeRO] Graft could reduce the morbidity and mortality associated with TDCs and have a profound impact on the costs associated with catheter related infections and interventions.”